{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T20:48:39Z","timestamp":1761511719126},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"912","license":[{"start":{"date-parts":[[2001,10,1]],"date-time":"2001-10-01T00:00:00Z","timestamp":1001894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2001,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:p>As a cause for hypertension, aldosterone excess is now thought to be more prevalent than previously quoted in textbooks. Classical features of hypokalaemia and metabolic alkalosis can be absent even in the presence of marked hypertension. This implies the need for a high index of suspicion and possibly argues the case for routine screening, especially in patients with \u201cdifficult to treat\u201d hypertension. Given multisystem target organ damage and increased cardiovascular risk associated with chronic uncontrolled hypertension, a readily treatable cause such as hyperaldosteronism is an important diagnosis to make. In addition, hyperaldosteronism related hypertension is now known to cover other recently identified monogenic disorders such as glucocorticoid remediable aldosteronism. These rarer monogenic hypertensive disorders provide clues to cracking the mystery behind polygenic \u201cessential\u201d hypertension. Apart from patients with hyperaldosteronism, a subset of the well recognised \u201clow renin hypertension\u201d patient group also appears to produce a dramatic and remarkable response when treated with spironolactone. We suggest that spironolactone sensitive hypertension may represent a wider spectrum of disorders where blood pressure is readily controlled by the addition of aldosterone receptor antagonist.<\/jats:p>","DOI":"10.1136\/pmj.77.912.639","type":"journal-article","created":{"date-parts":[[2002,7,27]],"date-time":"2002-07-27T10:30:44Z","timestamp":1027765844000},"page":"639-644","source":"Crossref","is-referenced-by-count":25,"title":["Hyperaldosteronism: recent concepts, diagnosis, and management"],"prefix":"10.1093","volume":"77","author":[{"given":"R","family":"Foo","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Unit, University of Cambridge , Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K M","family":"O'Shaughnessy","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, University of Cambridge , Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M J","family":"Brown","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Unit, University of Cambridge , Box 110, Addenbrooke's Hospital, Cambridge CB2 2QQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2001,10,1]]},"reference":[{"key":"2023042613395233700_B1","first-page":"2031","article-title":"Characterization of sgk, a novel member of the serine\/threonine protein kinase family which is transcriptionally induced by glucocorticoids and serum.","volume":"13","author":"Webster","year":"1993","journal-title":"Mol Cell Biol"},{"key":"2023042613395233700_B2","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1073\/pnas.96.5.2514","article-title":"Epithelial sodium channel regulated by aldosterone-induced protein sgk.","volume":"96","author":"Chen","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2023042613395233700_B3","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1210\/mend-3-9-1369","article-title":"Aldosterone induces a rapid increase in the rate of Na\/K-ATPase gene transcription in cultured kidney cells.","volume":"3","author":"Verrey","year":"1989","journal-title":"Mol Endocrinol"},{"key":"2023042613395233700_B4","first-page":"3517","article-title":"Rapid cardiovascular action of aldosterone in man.","volume":"83","author":"Wehling","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2023042613395233700_B5","first-page":"6","article-title":"Primary aldosteronism: a new clinical syndrome.","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"2023042613395233700_B6","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(05)74868-6","article-title":"Potentially high prevalence of primary aldosteronism in a primary-care population.","volume":"353","author":"Lim","year":"1999","journal-title":"Lancet"},{"key":"2023042613395233700_B7","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","article-title":"A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity. Results in hypertensive patients.","volume":"141","author":"Hiramatsu","year":"1981","journal-title":"Arch Intern Med"},{"key":"2023042613395233700_B8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0140-6736(94)93003-1","article-title":"Mineralocorticoid hypertension.","volume":"344","author":"Gordon","year":"1994","journal-title":"Lancet"},{"key":"2023042613395233700_B9","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0140-6736(00)04223-9","article-title":"Cautions over the current epidemic of primary aldosteronism.","volume":"357","author":"Kaplan","year":"2001","journal-title":"Lancet"},{"key":"2023042613395233700_B10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1046\/j.1365-2125.1999.00070.x","article-title":"Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.","volume":"48","author":"Lim","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"2023042613395233700_B11","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1440-1681.1985.tb02641.x","article-title":"Is aldosterone\/renin ratio useful to screen a hypertensive population for primary aldosteronism?","volume":"12","author":"Hamlet","year":"1985","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2023042613395233700_B12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1440-1681.1991.tb01446.x","article-title":"Clinical and pathological diversity of primary aldosteronism including a new familial variety.","volume":"18","author":"Gordon","year":"1991","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2023042613395233700_B13","doi-asserted-by":"crossref","DOI":"10.1016\/S0272-6386(01)80117-7","article-title":"Screening for primary aldosteronism without discontinuing hypertensive medications: the plasma aldosterone-renin ratio","volume-title":"Am J Kidney Dis","author":"Gallay"},{"key":"2023042613395233700_B14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/355262a0","article-title":"A chimeric 11\u03b2-hydroxlase\/aldosterone synthase and human hypertension.","volume":"355","author":"Lifton","year":"1992","journal-title":"Nature"},{"key":"2023042613395233700_B15","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1126\/science.289.5476.119","article-title":"Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy.","volume":"289","author":"Geller","year":"2000","journal-title":"Science"},{"key":"2023042613395233700_B16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/01.HYP.34.3.388","article-title":"Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension.","volume":"34","author":"Fisher","year":"1999","journal-title":"Hypertension"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/77\/912\/639\/50042884\/postgradmedj-77-639.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/77\/912\/639\/50042884\/postgradmedj-77-639.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T13:41:00Z","timestamp":1682516460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/77\/912\/639\/7039498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,10,1]]},"references-count":16,"journal-issue":{"issue":"912","published-online":{"date-parts":[[2001,10,1]]},"published-print":{"date-parts":[[2001,10,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pmj.77.912.639","relation":{},"ISSN":["1469-0756","0032-5473"],"issn-type":[{"value":"1469-0756","type":"electronic"},{"value":"0032-5473","type":"print"}],"subject":[],"published-other":{"date-parts":[[2001,10]]},"published":{"date-parts":[[2001,10,1]]}}}